The FDA awards Fast Track designation to BW-20805 for hereditary angioedema, a therapy designed to reduce attacks through PKK ...
The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results